Clinical Trials Logo

Clinical Trial Summary

Spontaneous, pharmacological observational, no-profit, retrospective, multi-center. This study was designed to get a "real-life" snapshot across several Italian Hepatology centers. All HDV patients are followed up according to EASL 2017 guidelines. This allows uniformity on the indication for antiviral treatment and management of that antiviral therapy. No off-label medications are used. All data are retrievable from the patient's medical record. In addition, clinical and biochemical data from patients at month 0, 1, 2, 4, 6 and 12 of treatment, and otherwise within the study period, will be collected retrospectively/longitudinally. The primary objective of the study is to describe the virological response to BLV in all patients starting BLV therapy, defined as a >2 Log decline in HDV-RNA or undetectable HDV-RNA (using the Robogene 2.0 quantitative kit, LLQ <6 IU/ml) at month 12 of therapy. All patients with active HDV chronic hepatopathy (quantifiable HDV-RNA) who initiated treatment with BLV 2 mg/day during the study period at the S.C. Gastroenterology and Hepatology (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico) and at participating centers, and who met the inclusion criteria and none of the exclusion criteria.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05962307
Study type Observational
Source Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Contact
Status Completed
Phase
Start date April 1, 2023
Completion date May 31, 2023

See also
  Status Clinical Trial Phase
Completed NCT02044055 - Mother-to-child Hepatitis D Transmission N/A
Completed NCT02375906 - The Hepatitis Delta International Network
Not yet recruiting NCT05394623 - Prevalence and Burden of Hepatitis D Virus Infection in China Through Preoperative Examination Test (Predict Study)
Recruiting NCT04863703 - Improvement of Portal Hypertension During Viral Suppression in Patients With Hepatitis Delta (IMPHROVE-D)
Not yet recruiting NCT06397859 - Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis
Recruiting NCT00001971 - Evaluation of Patients With Liver Disease
Recruiting NCT06122285 - Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD)
Recruiting NCT05928000 - HEllenic Multicenter ReAl-life CLInical Study for Bulevirtide Therapy in Chronic Hepatitis D: HERACLIS-BLV
Terminated NCT04847440 - A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection Phase 2
Not yet recruiting NCT06264583 - HDV-Europe: Prevalence and Outcome of HDV in HIV/HBV Coinfection
Recruiting NCT05936073 - DELTA DESCRIBE: the French Collaborative Project
Completed NCT00932971 - HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis Phase 2
Completed NCT06360484 - Prevalence and Clinical Characterization of Hepatitis D Virus (HDV) Infection Among Sudanese Patients With Hepatitis B Virus
Completed NCT02511431 - Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir Phase 2
Not yet recruiting NCT05451082 - Registry-based Study in Patients With Hepatitis D Virus (HDV) Infection in China
Recruiting NCT05903742 - Standardising Care for Hepatitis Delta in the Netherlands
Not yet recruiting NCT03362866 - Epidemiology of Hepatitis B, C and Delta in Reunion Island
Terminated NCT01316185 - Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV) Phase 1
Recruiting NCT05264272 - Disease Loads and Status of Treatment
Completed NCT05002907 - Epidemiology of Hepatitis B, C and D and HIV Along the Maroni River Bordering French Guiana and Suriname (MaHeVi)